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Background: Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity
and mortality worldwide. Diagnosis is customarily confirmed with spirometry, but there are
few studies on documented spirometry use in everyday clinical practice.
Methods: In a cross-sectional survey and study of the medical records of primary and
secondary care COPD patients aged 18e75 in a Swedish region, patients with COPD were
randomly selected from the registers of 56 primary care centres and 14 hospital outpatient
clinics. Spirometry data at diagnosis 6 months were analyzed.
Results: From 1114 patients with COPD, 533 with a new diagnosis of COPD during the four-
year study period were identified. In 59% (nZ 316), spirometry data in connection with diag-
nosis were found in the medical records. Spirometry data with post-bronchodilator forced
expiratory volume in 1 s (FEV1)/ vital capacity (VC) ratios were available in 45% (nZ 241).
FEV1/VC ratio <0.70 were found in 160 patients, which corresponds to 30% of the
patients with a new diagnosis. Lower age, female gender, current smoking, higher body mass
index (BMI) and shorter forced exhalation time were related to COPD diagnosis despite
an FEV1/VC ratio of 0.70. The most common problem in the quality assessment was an
insufficient exhalation time.06533259; fax: þ46 54615953.
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Diagnosis of COPD e Confirmed with spirometry? 551Conclusions: Only a third of Swedish patients with COPD had their diagnosis confirmed with
spirometry. Our data indicate that female gender, current smoking, higher BMI and short
exhalation time increase the risk of being diagnosed with COPD without fulfilling the spiro-
metric criteria for the disease.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is an impor-
tant cause of morbidity and mortality. Its prevalence and
morbidity data often underestimate the burden of disease
because this disease is not diagnosed until it is clinically
apparent and moderately advanced.1 COPD has in previous
guidelines been defined as ‘‘a chronic, slowly progressive
disorder characterized by airflowobstruction (reduced forced
expiratory volume in 1 s (FEV1) and FEV1/VC (vital capacity)
ratio) that does not change markedly over several months’’.2
However, in recent guidelines, COPD is also regarded as
a preventable and treatable disease.1,3 Thus, early detection
and correct diagnosis are extremely important.
Spirometry is essential for diagnosis, providing a useful
description of the severity of pathological changes in
COPD.3 Guidelines have been produced regarding the
standardization of spirometry, the diagnosis and manage-
ment of COPD and different spirometric criteria exist.4 The
disease is frequently under-diagnosed, but can also be
over-diagnosed.5e12 Epidemiological surveys and clinical
investigations alike have reported patients with a diagnosis
of COPD but normal lung function.13e15
The majority of patients with COPD are nowadays diag-
nosed and managed in primary care, i.e. by general prac-
titioners or family physicians.16,17 Though spirometry in
primary care has become more readily available, it is
largely underused,17 31e37% of patients with COPD having
clinically documented spirometry data.18e21
Although good quality spirometric measurement is
possible and spirometry is the gold standard for diagnosing
COPD,3 there is no published empirical data on the effect of
inaccurate spirometric measurements in primary care.17
Further, it is questioned whether spirometry results are
being used systematically to make decisions which really
benefit patients with COPD.22
The Swedish National Board of Health and Welfare
produced guidelines for asthma and COPD in 2004.23 The
present study was intended to compare these guidelines
with the care actually performed between January 2000
and December 2003.24
The aims were to investigate how far documented
spirometry test results confirm the diagnosis of COPD in
primary and secondary care in mid-Sweden during the years
2000e2003, and to assess the quality of spirometry tests.Study population and methods
Procedure
In a region of seven counties in Sweden, primary care
centres and outpatient clinics at hospitals (secondary care)were stratified by county and then randomly selected. Eight
primary care centres and two secondary care clinics per
county were selected; in total 56 primary care centres and
14 outpatient clinics. Each centre in primary care and each
clinic in secondary care generated a list of all patients with
a diagnosis of COPD (International Classification of
Diseases, tenth revision, ICD-10-code J44) attending the
centre or clinic during the previous four years in the age
range of 18e75 years. From the lists in primary care,
random samples of 22 patients were drawn. At centres with
fewer than 22 patients, all patients were sampled, giving
a total of 1084 patients. From each list in secondary care,
random samples of 35 patients were drawn. At clinics with
fewer than 35 patients, all patients were sampled, gener-
ating a total of 464 patients from secondary care. A ques-
tionnaire was sent to the patients with two reminders when
necessary and returned by a total of 76%. There was no
difference in gender distribution, but there was a differ-
ence in mean age between respondents and non-respon-
dents; 64.0 and 62.7 years respectively (pZ 0.009). Of the
respondents, 98% gave permission to collect data from their
medical records. Data from 778 patients in primary care
and 336 patients in secondary care were possible to eval-
uate. From these 1114 patients with COPD, all those with
a specified date for new diagnosis of COPD during the study
period were identified (nZ 533).
Data collection
Data from medical records from 2000 to 2003 inclusive were
abstracted and analyzed by two research nurses. Data on
current smoking habits were obtained via a questionnaire
sent to the patients in 2005. Questions about smoking
habits were ‘‘Do you smoke?’’ with the alternatives: No, I
have never smoked regularly/No, I have stopped smoking/
Yes, I smoke occasionally/Yes, I smoke daily and an open
question: ‘‘If you smoke or earlier have smoked daily e How
many years have you smoked daily?’’
Diagnostic spirometry
Diagnostic spirometry was defined as spirometry performed
during the interval starting six months prior to diagnosis of
COPD and ending six months after the date of diagnosis.
Spirometry data used were any pre- or post-bronchodilator
values from either FEV1, FEV1 percent predicted or FEV1/VC
ratio in spirometry reports or in medical records. Predicted
values were according to, or transformed to, European
Community for Steel and Coal (ECSC) reference values.25
Post-bronchodilator FEV1/VC ratios were obtained from
records or calculated,where thehighestVCvalue froma slow
vital capacity test (SVC) or a forced manoeuvre, forced vital
capacity (FVC) was used according to American Thoracic
552 M. Arne et al.Society (ATS)/European Respiratory Society (ERS) criteria.26
If several spirometry tests had beenperformed, the onemost
closely preceding the date of diagnosis was chosen e one
spirometry per patient. Spirometry devices used were
pneumotachographs, ultrasound sensors or turbine trans-
ducers with computer software from several manufacturers.
Quality criteria: assessment of spirometry curves
Available flowevolume and volumeetime curves were
analyzed visually by MA (first author) and reviewed by HH
(specialist in pulmonary physiology). The best curve e the
one with the largest sum of FEV1 and FVC was consequently
used for analysis. According to guidelines current during the
study period (ATS 1995),27 acceptability criteria were:
having good starts, free from artefacts, and showing satis-
factory exhalation. Our analysis included visual inspection of
the flowevolume curves, which were scored ‘‘acceptable’’
or ‘‘not acceptable’’: start of test (steep upslope), shape of
peak (sharp) and artefacts (no artefacts during the first
second). End-of-tests were assessed in both the flow-volume
curves (no cut-off) and volume-time curves (acceptable
plateau). Forced expiratory time (FET) (limit6 s) was
estimated from the volumeetime curves and expressed in
seconds to the lower half second.
Statistical methods
T tests were used for analyzing continuous data. For non-
parametric data chi-square tests were used with Yates’New diagnosis of COPD during the study period
n=533 
Spirometry data available in connection 
with diagnosis
n=316 (59%) 
Post-bronchodilator FEV1/VC ra-
tio and data available 
n=241 (45%) 
Post-bronchodilator 
FEV1/VC ratio 
< 0.70 
n=160 (30%) 
Figure 1 Availability of spirometry data in medical recocorrected chi-square (continuity correction) computed for
all 2 2 tables. Two-sided p values of <0.05 were consid-
ered statistically significant. The data were analyzed using
statistical software (SPSS; Statistical Package for the Social
Sciences 15.0).
Ethics
The Research Ethics Board at Uppsala University, Sweden,
approved the study (Dnr 2004:M-445).
Results
Diagnostic spirometry
Of the 533 patients with new diagnosis of COPD, diagnostic
spirometry data were available in 59% (316 patients) (Figs. 1
and 2). Patients with spirometry data were younger. In
patients aged below 50 years, 76% had spirometry data,
versus 64% in patients 50e65 years and 51% in those over
65 years (pZ 0.001) (Table 1). Men >50 years were more
likely to have spirometry data than were women >50 years
(pZ 0.004). Spirometry data were more absent in primary
care records: 47% versus 20% in secondary care (p< 0.001).
Post-bronchodilator spirometry data including FEV1/VC
ratio were available in 241 patients 45% of all those with
new diagnoses (Figs. 1 and 2). Patients with post-broncho-
dilator data had more smoking years than those without
such data (Table 2). 
Diagnosis without docu-
mented spirometry data to
confirm diagnosis
n=217 (41%) 
No post-
broncho-
dilator 
FEV1/VC
ratio or
data 
n=75 
(14%) 
Post-
broncho-
dilator 
FEV1/VC 
ratio 0.70
n=81
(15%) 
≥
rds in patients with new diagnosis of COPD (nZ 533).
Post-bronchodilator 
FEV1/VC ratio ≥ 0.70
15% No post-bronchodilator 
FEV1/VC ratio or data
14%
No spirometry data
41%
Post-bronchodilator 
FEV1/VC ratio <0.70
30%
Figure 2 Distribution of post-bronchodilator spirometry data
and absence of data in medical records in patients with new
diagnosis of COPD (nZ 533).
Diagnosis of COPD e Confirmed with spirometry? 553In the 241 patients with post-bronchodilator data, 81
(34%) had a post-bronchodilator FEV1/VC ratio above the
diagnostic criterion of 0.703 (Table 3). This group was
younger, contained more women, had a higher body mass
index and was more often current smokers. More than half
had in addition a predicted FEV1 of over 80%, equivalent to
FEV1 limits for COPD in the NICE guidelines.
28
Quality of spirometry
Flowevolume curves were available for 207 patients and
55% of these fulfilled the present quality criteria (Table 4).
Volumeetime curves were available for 119 patients and
34% of these fulfilled the criteria.
Acceptable quality was found for the start, peak and
no-artefacts criteria in more than 90% of the tests (Table 4),
while end-of-test was reached in 64e65% and FET 6 s in
51%. Further, FET 6 s was present in 14% of the patients
under 50 years and 67% of patients over 65 years (pZ 0.002).
In 24%, 75 out of 316, of the spirometry tests performed in
connectionwith diagnosis, there were no post-bronchodilator
values or FEV1/VC ratio (Fig. 1). Post-bronchodilator values ofTable 1 Characteristics of the study population stratified by wh
diagnosis of COPD, mean (SD) or percentage (nZ 533).
Characteristics New diagnosis
(nZ 533)
Age, yrs 60.1 (8.0)
Gender, female, % 58
Body mass index (kg/m2) 26.3 (5.0)
Smoking status,a %
Current smokers 40
Years smoking,a yrs 36.1 (11.5)
Highest educational level, %
Compulsory school 63
Grammar school/University 37
Spirometry data within each age group, %
<50 Years
50e65 Years
>65 Years
Setting; primary care, % 76
a Smoking according to patient questionnaire in 2005.SVC were recorded in one-quarter and FVC in three-quarters
of patients who underwent spirometry. In the reports giving
both values (nZ 65), 40% had a post-bronchodilator FVC
higher than SVC.
Discussion
The present study describes the documentation of spirom-
etry data in medical records for patients with a new diag-
nosis of COPD. Only 30% had a diagnosis verified by
spirometry data and all quality criteria were met in
between 34% and 55% of the spirometry curves.
In 2000, spirometers were available at 77% of primary
care centres in the region investigated in Sweden29 versus
93% in 2005 in the present study. This tallies with a study
from western Sweden,30 where 95% of primary care centres
had access to a spirometer. This is a high prevalence
compared with other countries. In Wales,19 82% had
a spirometer versus 66% in Vermont, USA.31
We describe documentation of spirometry in both
primary care and hospital outpatient clinics and illustrate
everyday clinical practice in a region. Patients with COPD
were randomly selected from the diagnosis registers. This
could result in a selection of patients with an established
diagnosis and more severe COPD in comparison with
patients with minor symptoms and without registered COPD
diagnoses e perhaps labelled with asthma diagnoses and
not COPD.
It was not possible to assess in detail the start of the
forced manoeuvre with possible overestimation of FEV1
because of sub-maximal efforts and/or hesitation in the
start-of-test phase as described in the BRONCUS study.32
The between-manoeuvre criterion repeatability33 could not
be assessed in a standardized manner because of the
different devices and software used. Moreover in most
cases there was only one curve, ‘‘the best curve’’ e the one
with the largest sum of FEV1 and FVC in the report.
Spirometry datawere available in records for 59% of ‘‘our’’
patients with new COPD diagnoses, and post-bronchodilatorether spirometry data were available in connection with new
Spirometry data
(nZ 316)
No spirometry data
(nZ 217)
p Value
59.2 (8.3) 61.4 (7.4) 0.002
56 61 0.232
26.1 (4.8) 26.7 (5.3) 0.176
0.836
41 40
35.9 (11.2) 36.4 (12.0) 0.671
0.324
61 66
39 34
0.001
76 24
64 36
51 49
68 89 <0.001
Table 2 Spirometry data post-bronchodilator and FEV1/VC ratio and no post-bronchodilator data or FEV1/VC ratio, mean (SD)
or percentage (nZ 316).
Spirometry post-bronchodilator
and FEV1/VC ratio (nZ 241)
No spirometry post-bronchodilator
or FEV1/VC ratio (nZ 75)
p Value
Age, yrs 59.2 (8.4) 59.0 (7.9) 0.819
Gender, female, % 53 64 0.127
Body mass index (kg/m2) 26.2 (4.9) 25.7 (4.5) 0.403
Smoking status,a % 43 33 0.169
Current smokers
Years smoking,a yrs 36.8 (10.9) 33.1 (11.8) 0.015
Pre-bronchodilator 62.0 (22.1) 66.1 (23.3) 0.280
FEV1 % pred
b
Pre-bronchodilator 0.60 (0.14) 0.62 (0.15) 0.285
FEV1/VC ratio
Setting; primary care, % 69 65 0.616
a Smoking according to patient questionnaire in 2005.
b Pred: predicted value according to ECSC.25.
554 M. Arne et al.values were included in 76% of these. Our results are higher
than data from health plans in a United States (US) study,18
where 32% of patients with new COPD diagnoses had under-
gone spirometry with post-bronchodilator values in 46% of
these patients. In primary care in Spain 34 spirometric results
were obtained in 58% of patients diagnosed with COPD
andwith post-bronchodilator data in 55% of these patients. In
Wales,19 37% of spirometric confirmation was present, as
estimated fromonequestion to general practitioners,while in
the US Veterans Administration,20 34% of patients with new
diagnosis of COPD had undergone spirometry.
In our study, spirometry testing was less frequent in the
oldest (65e75 years) than in those 50e65 years old, and
most common in those under 50. This agrees with Lee
et al.20 where the likelihood of undergoing spirometry was
highest in patients <50 years old and became successively
lower with increasing age.Table 3 Patients with post-bronchodilator FEV1/VC ratio <0.70
FEV1/VC ratio <0.70
(nZ 160)
Age, yrs 60.6 (8.2)
Gender, female, % 47
Body mass index (kg/m2) 25.7 (4.9)
Smoking status,a % 37
Current smokers
Years smoking,a yrs 37.1 (11.4)
Post-bronchodilator 57.8 (18.9)
FEV1 % pred
b
Post-bronchodilator
FEV1 level, %
FEV1 80% 10
50% FEV1< 80% 55
FEV1< 50% 35
Post-bronchodilator VC 33
value (nZ 65)c; FVC> SVC
Setting; primary care, % 66
a Smoking according to patient questionnaire in 2005.
b Pred: predicted value according to ECSC.25.
c Post-bronchodilator data with both FVC and SVC values.Fifteen percent of our patients with newly diagnosed
COPD had an FEV1/VC ratio equal to or greater than 0.70
indicating no airflow limitation. Diagnosis based mainly on
clinical symptoms, not taking spirometric data into
consideration or misinterpreting available data could be
reasons for this over-diagnosis. A desire to alert smokers to
the danger of serious disease could perhaps be an expla-
nation of the high prevalence of women (with high smoking
rates) and younger persons in this group.
Other studies also describe a prevalence of COPD diag-
nosis not supported by spirometry data. In a study from
Italy,15 30% of patients receiving a new diagnosis of COPD
from general practitioners had normal spirometry. Tinkel-
man et al.35 found that among persons with prior diagnosis
of COPD only about half presented with obstruction. Almost
one-quarter of the same study population had post-
bronchodilator obstruction compatible with COPD but noand FEV1/VC ratio 0.70, mean (SD) or percentage (nZ 241).
FEV1/VC ratio 0.70
(nZ 81)
p Value
56.6 (8.2) <0.001
65 0.010
27.2 (4.8) 0.023
56 0.009
36.4 (9.8) 0.667
82.9 (18.3) <0.001
<0.001
54
39
7
62 0.044
76 0.112
Table 4 Quality criteria in post-bronchodilator FEV1/VC ratio <0.70 and FEV1/VC ratio 0.70, percentage (nZ 207).
Quality criteria All FEV1/VC ratio <0.70 FEV1/VC ratio 0.70 p Value
Flowevolume curve nZ 207 nZ 133 nZ 74
Start of test, steep upslope 94 94 93 0.984
Peak, sharp 94 97 88 0.087
No artefacts 93 92 93 0.938
End-of-test, no cut-off 64 61 69 0.178
All (4) criteria fulfilled 55 54 57 0.828
Volumeetime curve nZ 119 nZ 75 nZ 44 0.765
57% 56% 59%
End-of-test, acceptable plateaua 65 57 77 0.252
FET 6 sa 51 68 23 <0.001
All (2) criteria fulfilleda 34 44 18 0.008
FETZ forced expiratory time.
a Percentage of volumeetime curves.
Diagnosis of COPD e Confirmed with spirometry? 555prior diagnosis of COPD. The reason for this can also be
under-presentation of patients developing COPD as
described in studies in primary care.36,37 From the US, Yawn
et al.38 describe over-reporting of airflow obstruction in
those with normal results with confirmation of COPD in the
absence of an FEV1/FVC ratio below 0.70. In primary care in
Tasmania39 patients were mislabelled with a diagnosis of
COPD when FEV1/FVC was greater than 0.70.
For the individual, spirometry of good quality can be
important for ruling out COPD as diagnosis where there is no
airflow limitation but where a differential diagnosis is
possible.3
Despite the limited possibilities of analyzing in detail
the quality of performance parameters, there were indi-
cations that FET was the main parameter associated with
detection of airflow limitation. Visual analysis of only the
start, peak, artefacts or end-of-test from the curves
showed no clear relationship affecting the FEV1/VC ratio.
However FET 6 s was achieved by only 51% in our study,
indicating exhalations that were not maximal. In the
SA.R.A. study 40 of elderly subjects (>65 years), 83%
obtained FET 6 s, corresponding to 67% in patients >65
years in our study. Other studies have reported a mean FET
of 10.7 s in a population41 and 11.3 s in patients with
airflow obstruction.42
Some guidelines contain arguments for using SVC
manoeuvre in place of FVC because the ratio of FEV1 to SVC
can accurately identify more obstructed patients than can its
ratio to FVC.26 As present SVC values were seldom (in 24%)
recorded post-bronchodilator, the FEV1/VC ratio was often
calculated with FVC as denominator, possibly giving a higher
ratio in obstructed elderly patients, especially when FETs
wereshort. Thiscanbeoneexplanationof thehighprevalence
of FEV1/VC ratio0.70. It cannot, however, explain why over
half the patients with FEV1/VC ratios over 0.70 also had pre-
dicted FEV1 of over 80%. This might indicate that only a minor
airflow limitation was present and supports a suspicion of
misinterpretation of the spirometry data.
Further, the performance of the SVC manoeuvre as fully
relaxed cannot be validated in this study; but when both
values were present, 40% had FVC higher than SVC, while
the opposite would be expected in patients with airflow
limitation.43Conclusions
Seventy percent of patients with diagnosis of COPD lacked
spirometry results confirming the diagnosis. This shows that
high availability of spirometry equipment is not enough e it
must be used, with good quality and according to the
guidelines. Attention to quality is needed, with focus on,
e.g. the performance of maximal exhalation indicated by
the FET, which influences the VC value as the denominator
of the FEV1/VC ratio. Our data also indicate that female
gender, current smoking and higher BMI increase the risk of
being diagnosed with COPD without fulfilling the spiro-
metric criteria for the disease.
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